Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02260856 · ClinicalTrials.gov registry record · NA
A Randomized Controlled Trial of Leg Length Discrepancy Techniques
A NA study, sponsored by Hospital for Special Surgery, New York.
- Terminated
- Registry status
- NA
- Development phase
- 170
- Enrollment target
NCT02260856: Clinical Trial NA study, sponsored by Hospital for Special Surgery, New York.
NCT02260856 is a NA study that was terminated before completion, run by Hospital for Special Surgery, New York. The registered enrollment target is 170 participants, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (88% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT02260856, a NA study, was terminated before completion, sponsored by Hospital for Special Surgery, New York.
- TERMINATED
- Registry status
- NA
- Development phase
- 170 participants
- Enrollment target
Study Summary
This is a randomized clinical trial of epiphysiodesis techniques: percutaneous transphyseal screw epiphysiodesis versus percutaneous drill epiphysiodesis for the correction of leg length discrepancy. Failed epiphysiodesis was selected as the primary outcome. Failed epiphysiodesis was defined as one or more of the following: development of angular deformity \> 5°, revision epiphysiodesis, or growth inhibition \< 70% of expected. EOS, low dose biplanar X-Ray, will be used to make all length measurements. Secondary outcomes assess mean growth at the physis following epiphysiodesis, in the subset of patients with bead implantation, fluoroscopy and operative times, length of stay, return to full weight bearing, as well as functional and quality of life outcomes. The following outcome scales will be used to measure pain (VAS), quality of life (PROMIS Pediatric Pain Interference Scale), and function (PROMIS Pediatric Mobility Scale, Pedi-FABS, and UCLA Activity Score). Each of these scales has been validated for use in children (Beyer, Denyes, \& Villarruel, 1992; DeWitt et al., 2011; Fabricant et al., 2013; Novais et al., 2014; Varni et al., 2010a). We will also determine the cost associated with each technique and perform a cost-effectiveness analysis to establish which technique is preferred from a societal perspective.
Primary Outcome
development of angular deformity \> 5°, revision epiphysiodesis, or growth inhibition \< 70% of expected
Interventions
- DEVICE Tantalum Beads & Injector
- PROCEDURE Percutaneous Drill Epiphysiodesis
- PROCEDURE Percutaneous Screw Epiphysiodesis
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 170 participants |
| Start Date | 2015-06 |
| Est. Completion | 2023-12 |
| Phase | NA |
Why NCT02260856 stopped before completion
NCT02260856 is an interventional study that assigns participants to a tested intervention. The registered 170 participants enrollment target is mid-sized for trials with a published cap, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (88% lower).
The record links to 0 conditions, and to 3 interventions - of which Tantalum Beads & Injector is the first listed.
NCT02260856 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT02260856 about?
NCT02260856 is a clinical study titled "A Randomized Controlled Trial of Leg Length Discrepancy Techniques". This is a randomized clinical trial of epiphysiodesis techniques: percutaneous transphyseal screw epiphysiodesis versus percutaneous drill epiphysiodesis for the correction of leg length discrepancy. Failed epiphysiodesis was selected as the primary outcome. Failed epiphysiodesis was defined as one ...
What is the current status of trial NCT02260856?
This trial is currently terminated. It is a NA study. The enrollment target is 170 participants. The study started on 2015-06. Estimated completion is 2023-12.
What interventions are being tested in trial NCT02260856?
The interventions under investigation include: Tantalum Beads & Injector (DEVICE), Percutaneous Drill Epiphysiodesis (PROCEDURE), Percutaneous Screw Epiphysiodesis (PROCEDURE).
Who is sponsoring clinical trial NCT02260856?
This trial is sponsored by Hospital for Special Surgery, New York, which has 194 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT02260856's enrollment target sits among peer trials
170 614th of 2000 higher than 1,382 of 2,000 other NA trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other NA trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02016430 · 170 participants · NA
Gut Flora Metabolite Reduction After Dietary Intervention (GRADY)
- NCT02621021 · 170 participants · Phase 2
A Phase 2 Trial for Metastatic Melanoma Using Adoptive Cell Therapy With Tumor Infiltrating Lymphocytes Plus IL-2 Either Alone or Following the Administration of Pembrolizumab
- NCT04094701 · 170 participants · NA
Hip Arthroscopy Postoperative Opioid Demands
- NCT04166409 · 170 participants · Phase 3
A Study of the Drugs Selumetinib vs. Carboplatin and Vincristine in Patients With Low-Grade Glioma
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia